Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2003

View Archived Issues

New bradykinin B2 antagonists and their use as analgesics reported by AstraZeneca

Piperazine orexin antagonists in early development at GSK

New JNK inhibitors with utility in AD therapy reported in recent patent

Gruenenthal patent covers new alpha2A-AR ligands for pain and other uses

Novel methionine aminopeptidase type 2 inhibitors discovered by GSK scientists

AstraZeneca claims new cannabinoid CB1 receptor modulators

New alpha7 nAChR agonists under study at Bayer

AVP-893: a prototype of a novel class of antitumor agents designed at Avanir

Selective small-molecule inhibitors of CDK4 identified at Roche

Roche presents new series of antitumor agents targeting CDK2

Orally available Src tyrosine kinase inhibitor characterized in vitro and in vivo

Further preclinical characterization of AG-013736, a VEGFR/PDGFR TK inhibitor

VEGF receptor tyrosine kinase inhibitor E-7080, a promising agent for solid tumors

Efaproxiral reported to improve survival in cancer patients with brain metastases

MEDI-507 proven effective in a murine model of adult T-cell leukemia

Improved survival with carvedilol compared to metoprolol in chronic heart failure

Synthetic Hsp90 ATPase inhibitor identified as potential new lead anticancer agent

Barrier Therapeutics licenses oral vitamin D3 derivative

Genmab expands pipeline with hepatitis antibody

Phase II clinical trial of advanced malaria vaccine to begin in Mozambique

United Therapeutics files IND for i.v. Remodulin

Encouraging results from ongoing phase I/II trial with MetXia in breast cancer

Aastrom Biosciences receives third NIH grant for stem cell research

FDA clears phase I study of PHP as an adjunct to IL-2 cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...